Tracy Zimmermann is Chief Scientific Officer of City Therapeutics. She brings over 20 years of experience in drug development, with a focus on genetic medicines, and a proven track record of scaling innovative modalities like gene therapy and RNAi therapeutics.

Prior to City, Dr. Zimmermann was the Chief Development Officer at Generation Bio (subsequently acquired by XOMA Royalty Corp.), where she led the pharmacology, toxicology, and DMPK groups to advance the company’s non-viral gene therapy platform from research into preclinical development for liver and extrahepatic indications. Previously, Dr. Zimmermann spent 15 years at Alnylam Pharmaceuticals in numerous roles within research spanning RNAi platform enablement to early program development. While at Alnylam she contributed to the advancement of ONPATTRO®, GIVLAARI®, and AMVUTTRA®.

Earlier in her career, Dr. Zimmermann was a Senior Scientist at Variagenics (subsequently merged with Hyseq Pharmaceuticals, which was renamed Nuvelo). She completed a National Institutes of Health postdoctoral fellowship at Harvard Medical School/Dana-Farber Cancer Institute. She received a B.S. in Biochemistry from Lehigh University and a Ph.D. in Chemistry from the University of Colorado Boulder.